SCHEMBL13826650

SCHEMBL13826650

Cc1ccnc(Nc2cc(C)cc(Br)n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 3/20 0.55
▸ KDR P35968 2/20 0.52
▸ MAP4K4 O95819 1/20 0.52
▸ ABL1 P00519 1/20 0.52
▸ LCK P06239 1/20 0.52
▸ FYN P06241 1/20 0.52
▸ IGF1R P08069 1/20 0.52
▸ LTK P29376 1/20 0.52
▸ MAP2K2 P36507 1/20 0.52
▸ MAPK8 P45983 1/20 0.52
▸ MAPK9 P45984 1/20 0.52
▸ CLK2 P49760 1/20 0.52
▸ GSK3A P49840 1/20 0.52
▸ GSK3B P49841 1/20 0.52
▸ CDK7 P50613 1/20 0.52
▸ CDK9 P50750 1/20 0.52
▸ CDK5 Q00535 1/20 0.52
▸ MAP2K1 Q02750 1/20 0.52
▸ ACVR1 Q04771 1/20 0.52
▸ PTK2 Q05397 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16820071 0.87 SYK (0.44) SYKKDRMAP4K4ABL1LCK
SCHEMBL13726219 0.85 TRPV4 (0.44) SYKKDRMAP4K4ABL1LCK
SCHEMBL16840109 0.85 SYK (0.52) SYKKDRMAP4K4ABL1LCK
SCHEMBL15634682 0.85 SYK (0.45) SYKKDRMAP4K4ABL1LCK
SCHEMBL13739240 0.84 SYK (0.55) SYK
SCHEMBL13726067 0.84 SYK (0.62) SYK
SCHEMBL901321 0.83 KARS1 (0.57) SYKKDRMAP4K4ABL1LCK
SCHEMBL2912518 0.83 KDR (0.57) SYKKDRMAP4K4ABL1LCK
SCHEMBL16876408 0.82 SYK (0.52) SYK
SCHEMBL13826649 0.82 SYK (0.47) SYKKDRMAP4K4ABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2863914-B1 PYRAZOLYL DERIVATIVES AS SYK INHIBITORS MERCK SHARP & DOHME (US) 2018-10-03 — — EP disclosed
EP-2863913-B1 IMIDAZOLYL ANALOGS AS SYK INHIBITORS MERCK SHARP & DOHME (US) 2018-09-12 — — EP disclosed
EP-2707357-B1 PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS MERCK SHARP & DOHME (US) 2017-01-18 — — EP disclosed
US-9487504-B2 Imidazolyl analogs as syk inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-08 — — US disclosed
US-9487504-B2 Imidazolyl analogs as syk inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-08 — — US disclosed
US-9487504-B2 Imidazolyl analogs as syk inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-08 — — US disclosed
US-9242984-B2 Pyrazolyl derivatives as Syk inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 — — US disclosed
US-9242984-B2 Pyrazolyl derivatives as Syk inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 — — US disclosed
US-9242984-B2 Pyrazolyl derivatives as Syk inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 — — US disclosed
US-9145391-B2 Bipyridylaminopyridines as Syk inhibitors MERCK SHARP & DOHME CORP. (US) 2015-09-29 — — US disclosed
US-20150191461-A1 PYRAZOLYL DERIVATIVES AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-09 — — US disclosed
US-20150191461-A1 PYRAZOLYL DERIVATIVES AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-09 — — US disclosed
US-20150191461-A1 PYRAZOLYL DERIVATIVES AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-09 — — US disclosed
US-20150175575-A1 IMIDAZOLYL ANALOGS AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2015-06-25 — — US disclosed
US-20150175575-A1 IMIDAZOLYL ANALOGS AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2015-06-25 — — US disclosed
US-20150175575-A1 IMIDAZOLYL ANALOGS AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2015-06-25 — — US disclosed
US-20140249130-A1 BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2014-09-04 — — US disclosed
US-20140249130-A1 BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2014-09-04 — — US disclosed
US-20140100250-A1 PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2014-04-10 — — US disclosed
WO-2012154518-A1 BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191461-A1 PYRAZOLYL DERIVATIVES AS SYK INHIBITORS SYK, BTK, LCK SYK 1/4885KDR 1329/4885MAP4K4 410/4885
US-20140249130-A1 BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS SYK, BTK, LCK SYK 1/4885KDR 584/4885MAP4K4 363/4885
US-20140100250-A1 PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS SYK, BTK, LCK SYK 1/4885KDR 982/4885MAP4K4 385/4885
US-20150175575-A1 IMIDAZOLYL ANALOGS AS SYK INHIBITORS SYK, BTK, LCK SYK 1/4885KDR 1408/4885MAP4K4 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback